June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Characterizing cellular senescence to prevent retinal ganglion cell loss in glaucoma
Author Affiliations & Notes
  • Chris Louche
    Ophthalmology I2O, F Hoffmann-La Roche AG, Basel, Basel-Stadt, Switzerland
    Universitat Basel Department Biozentrum, Basel, Basel-Stadt, Switzerland
  • Praveena Manogaran
    Ophthalmology I2O, F Hoffmann-La Roche AG, Basel, Basel-Stadt, Switzerland
  • Nadine Colé
    Ophthalmology I2O, F Hoffmann-La Roche AG, Basel, Basel-Stadt, Switzerland
  • Peter Westenskow
    Ophthalmology I2O, F Hoffmann-La Roche AG, Basel, Basel-Stadt, Switzerland
  • Joana Galvao
    Ophthalmology I2O, F Hoffmann-La Roche AG, Basel, Basel-Stadt, Switzerland
  • Footnotes
    Commercial Relationships   Chris Louche F. Hoffmann-La Roche Ltd., Code E (Employment); Praveena Manogaran F. Hoffmann-La Roche Ltd., Code E (Employment); Nadine Colé F. Hoffmann-La Roche Ltd., Code E (Employment); Peter Westenskow F. Hoffmann-La Roche Ltd., Code E (Employment); Joana Galvao F. Hoffmann-La Roche Ltd., Code E (Employment)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 930 – A0399. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Chris Louche, Praveena Manogaran, Nadine Colé, Peter Westenskow, Joana Galvao; Characterizing cellular senescence to prevent retinal ganglion cell loss in glaucoma. Invest. Ophthalmol. Vis. Sci. 2022;63(7):930 – A0399.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Cellular senescence has been reported in human glaucoma patients and in a glaucoma mouse model. Mechanisms of senescence in the retina, and cell types implicated in this detrimental phenotype and propagation, remain incompletely understood. We aim to investigate the implication of senescence and identify the cells involved using the experimental model of retinal ischemia-reperfusion (I/R) injury in mice with the goal to prevent retinal degeneration.

Methods : Intraocular pressure (IOP) was increased in mice for 60 minutes by doing intracameral injection of elevated saline solution. In vivo and ex vivo measurements have been performed at different time points, up to 14 days post I/R injury. Visual acuity was evaluated using optokinetic response (OKR) tracking. Structural changes were assessed using optical coherence tomography (OCT). Retinal ganglion cell (RGC) degeneration was quantified on retinal flatmounts by counting BRN3A immunostained positive cells. qPCR on retinal lysates and immunohistochemistry was utilized in order to assess spatiotemporal patterns of senescence. For all analyses, the contralateral eye has been used as control and statistics have been performed using paired t-test.

Results : We observed a visual acuity dysfunction using OKR of the injured eye compared to control (-0.111 cycle/degree, p=0.016, n=4) at day 6. Despite being insignificant, thinning of the inner retinal layer after 14 days was noticed using OCT. RGC degeneration was measured with a loss of 59.24% at day 7 (p=0.018, n=4) and 36.28% at day 14 (p=0.030, n=6). We observed upregulation of senescence related genes in injured retinas compared to control at day 2: Cxcl1, Cdkn2b, Cdkn1a and day 7: Cxcl1, Il-1a. Using immunostaining, senescence markers were detected in injured retinas at day 2: P16INK4A and PAI1 were expressed in microglia and/or macrophages and Y-H2AX in RGCs and photoreceptors.

Conclusions : Evidence of cellular senescence is detectable in the retina following I/R insult. Several retinal cell types appear to be involved. However, what are the specific cell types that express and/or propagate the phenotype remain unclear. Therefore, to elucidate this we are planning to do single cell RNA sequencing to address these questions. In future steps will attempt to rescue the I/R senescent phenotype to improve visual acuity, with an ultimate goal of targeting cellular senescence in glaucoma patients for neuroprotection.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×